Advanced

CA 19-9 and CA 125 as potential predictors of disease recurrence in resectable lung adenocarcinoma

Isaksson, Sofi LU ; Jönsson, Per LU ; Monsef, Nastaran LU ; Brunnström, Hans LU ; Bendahl, Pär Ola LU ; Jönsson, Mats LU ; Staaf, Johan LU and Planck, Maria LU (2017) In PLoS ONE 12(10).
Abstract

Objectives: Among patients who underwent primary surgery for non-small cell lung cancer (NSCLC), recurrent disease is frequent and cannot be accurately predicted solely from TNM stage and histopathological features. The aim of this study was to examine the association of tumor markers in pre-operative serum with recurrent disease. Material and methods: Blood samples were collected prior to lung cancer surgery from 107 patients with stage I-III lung adenocarcinoma surgically treated at Lund University hospital, Lund, Sweden, between 2005 and 2011. The serum tumor markers Carcinoembryonic antigen (CEA), Neuron-specific enolase (NSE), Cancer antigen 125 (CA 125), Human epididymis protein 4 (HE4) and Carbohydrate antigen (CA 19–9) were... (More)

Objectives: Among patients who underwent primary surgery for non-small cell lung cancer (NSCLC), recurrent disease is frequent and cannot be accurately predicted solely from TNM stage and histopathological features. The aim of this study was to examine the association of tumor markers in pre-operative serum with recurrent disease. Material and methods: Blood samples were collected prior to lung cancer surgery from 107 patients with stage I-III lung adenocarcinoma surgically treated at Lund University hospital, Lund, Sweden, between 2005 and 2011. The serum tumor markers Carcinoembryonic antigen (CEA), Neuron-specific enolase (NSE), Cancer antigen 125 (CA 125), Human epididymis protein 4 (HE4) and Carbohydrate antigen (CA 19–9) were analyzed retrospectively and clinical follow-up data were collected from patient charts. Forty (37%) patients were diagnosed with recurrent disease. Results: Sixty-eight (64%) patients had at least one elevated tumor marker prior to surgery. In analysis of disease-free survival (DFS), CA 125 and/or CA 19–9 were significantly associated with recurrent disease adjusted to stage and adjuvant treatment (hazard ratio 2.8, 95% confidence interval 1.4–5.7, p = 0.006). Conclusion: High pre-operative serum CA 19–9 and/or CA 125 might indicate an increased incidence of recurrent disease in resectable lung adenocarcinomas.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
PLoS ONE
volume
12
issue
10
publisher
Public Library of Science
external identifiers
  • scopus:85031716346
  • wos:000413195900054
ISSN
1932-6203
DOI
10.1371/journal.pone.0186284
language
English
LU publication?
yes
id
578840a2-d6c1-4e0d-8c75-13a7d754888d
date added to LUP
2017-10-30 14:34:03
date last changed
2018-01-16 13:24:55
@article{578840a2-d6c1-4e0d-8c75-13a7d754888d,
  abstract     = {<p>Objectives: Among patients who underwent primary surgery for non-small cell lung cancer (NSCLC), recurrent disease is frequent and cannot be accurately predicted solely from TNM stage and histopathological features. The aim of this study was to examine the association of tumor markers in pre-operative serum with recurrent disease. Material and methods: Blood samples were collected prior to lung cancer surgery from 107 patients with stage I-III lung adenocarcinoma surgically treated at Lund University hospital, Lund, Sweden, between 2005 and 2011. The serum tumor markers Carcinoembryonic antigen (CEA), Neuron-specific enolase (NSE), Cancer antigen 125 (CA 125), Human epididymis protein 4 (HE4) and Carbohydrate antigen (CA 19–9) were analyzed retrospectively and clinical follow-up data were collected from patient charts. Forty (37%) patients were diagnosed with recurrent disease. Results: Sixty-eight (64%) patients had at least one elevated tumor marker prior to surgery. In analysis of disease-free survival (DFS), CA 125 and/or CA 19–9 were significantly associated with recurrent disease adjusted to stage and adjuvant treatment (hazard ratio 2.8, 95% confidence interval 1.4–5.7, p = 0.006). Conclusion: High pre-operative serum CA 19–9 and/or CA 125 might indicate an increased incidence of recurrent disease in resectable lung adenocarcinomas.</p>},
  articleno    = {e0186284},
  author       = {Isaksson, Sofi and Jönsson, Per and Monsef, Nastaran and Brunnström, Hans and Bendahl, Pär Ola and Jönsson, Mats and Staaf, Johan and Planck, Maria},
  issn         = {1932-6203},
  language     = {eng},
  month        = {10},
  number       = {10},
  publisher    = {Public Library of Science},
  series       = {PLoS ONE},
  title        = {CA 19-9 and CA 125 as potential predictors of disease recurrence in resectable lung adenocarcinoma},
  url          = {http://dx.doi.org/10.1371/journal.pone.0186284},
  volume       = {12},
  year         = {2017},
}